- Home
- ATLC vs CGEM Comparison
ATLC vs CGEM Comparison
Compare ATLC & CGEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ATLC | CGEM |
|---|---|---|
| Founded | 1996 | 2016 |
| Country | United States | United States |
| Employees | 417 | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 726.2M | 794.7M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | ATLC | CGEM |
|---|---|---|
| Price | $54.81 | $12.79 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 9 |
| Target Price | ★ $88.67 | $30.11 |
| AVG Volume (30 Days) | 58.4K | ★ 756.0K |
| Earning Date | 03-12-2026 | 03-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $472.00 | N/A |
| Revenue Next Year | $7.66 | $79.85 |
| P/E Ratio | $9.74 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $42.03 | $5.68 |
| 52 Week High | $78.91 | $16.74 |
Technical Indicators
Market Signals| Indicator | ATLC | CGEM |
|---|---|---|
| Relative Strength Index (RSI) | 50.17 | 40.60 |
| Support Level | $53.43 | $11.43 |
| Resistance Level | $58.10 | $13.21 |
| Average True Range (ATR) | 3.51 | 0.83 |
| MACD | 0.10 | -0.38 |
| Stochastic Oscillator | 58.12 | 1.27 |
Price Performance
Historical ComparisonAbout ATLC Atlanticus Holdings Corporation
Atlanticus Holdings Corp invests in the financial services industry. It provides various credit and related financial services and products to or associated with the financially underserved consumer credit market. The operating business segments are the Credit as a Service (CaaS) and the Auto Finance segment. It generates maximum revenue from the Credit as a Service segment.
About CGEM Cullinan Oncology Inc.
Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.